Rhenman & Partners Asset Management Ab Abb Vie Inc. Transaction History

Rhenman & Partners Asset Management Ab

$1.2 Billion
Q3 2024

A detailed history of Rhenman & Partners Asset Management Ab transactions in Abb Vie Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 177,000 shares of ABBV stock, worth $31.3 Million. This represents 2.91% of its overall portfolio holdings.

Number of Shares

177,000

Previous 189,000 6.35%

Holding current value

$31.3 Million

Previous $32.4 Million 7.82%

% of portfolio

2.91%

Previous 3.2%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$163.84 - $199.33 $1.97 Million - $2.39 Million	-12,000 Reduced 6.35%	177,000 $35 Million
Q2 2024 Aug 13, 2024	SELL	$154.79 - $180.76 $77,395 - $90,380	-500 Reduced 0.26%	189,000 $32.4 Million
Q1 2024 May 14, 2024	BUY	$159.82 - $182.1 $3.6 Million - $4.1 Million	22,500 Added 13.47%	189,500 $34.5 Million
Q4 2023 Feb 13, 2024	BUY	$137.6 - $154.97 $2.34 Million - $2.63 Million	17,000 Added 11.33%	167,000 $25.9 Million
Q2 2023 Aug 11, 2023	SELL	$132.51 - $164.9 $265,020 - $329,800	-2,000 Reduced 1.32%	150,000 $20.2 Million
Q1 2023 May 11, 2023	BUY	$144.61 - $166.54 $3.18 Million - $3.66 Million	22,000 Added 16.92%	152,000 $24.2 Million
Q4 2022 Feb 13, 2023	SELL	$138.31 - $165.87 $2.71 Million - $3.26 Million	-19,626 Reduced 13.12%	130,000 $21 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $5.42 Million - $6.21 Million	-40,374 Reduced 21.25%	149,626 $21.9 Million
Q2 2022 Aug 12, 2022	SELL	$137.62 - $174.96 $688,100 - $874,800	-5,000 Reduced 2.56%	190,000 $29.1 Million
Q1 2022 May 13, 2022	SELL	$131.98 - $163.75 $18.5 Million - $22.9 Million	-140,000 Reduced 41.79%	195,000 $31.6 Million
Q4 2021 Feb 11, 2022	SELL	$107.43 - $135.93 $2.15 Million - $2.72 Million	-20,000 Reduced 5.63%	335,000 $45.5 Million
Q3 2021 Nov 12, 2021	BUY	$106.4 - $120.78 $3.72 Million - $4.23 Million	35,000 Added 10.94%	355,000 $38.3 Million
Q2 2021 Aug 13, 2021	SELL	$105.21 - $117.21 $5.05 Million - $5.63 Million	-48,000 Reduced 13.04%	320,000 $36 Million
Q1 2021 May 14, 2021	SELL	$102.3 - $112.62 $13.5 Million - $14.9 Million	-132,000 Reduced 26.4%	368,000 $39.8 Million
Q4 2020 Jan 19, 2021	BUY	$80.49 - $108.67 $17.7 Million - $23.9 Million	220,000 Added 78.57%	500,000 $53.6 Million
Q3 2020 Oct 13, 2020	SELL	$85.91 - $100.83 $1.72 Million - $2.02 Million	-20,000 Reduced 6.67%	280,000 $24.5 Million
Q2 2020 Jul 16, 2020	SELL	$73.37 - $98.18 $2.2 Million - $2.95 Million	-30,000 Reduced 9.09%	300,000 $29.5 Million
Q1 2020 Apr 16, 2020	BUY	$64.5 - $97.79 $7.74 Million - $11.7 Million	120,000 Added 57.14%	330,000 $25.1 Million
Q4 2019 Jan 17, 2020	BUY	$72.13 - $90.25 $2.89 Million - $3.61 Million	40,000 Added 23.53%	210,000 $18.6 Million
Q3 2019 Oct 16, 2019	BUY	$62.98 - $75.72 $10.7 Million - $12.9 Million	170,000 New	170,000 $12.9 Million
Q2 2019 Jul 22, 2019	SELL	$65.7 - $83.98 $3.94 Million - $5.04 Million	-60,000 Closed	0 $0
Q1 2019 Apr 11, 2019	SELL	$77.14 - $90.79 $7.9 Million - $9.3 Million	-102,415 Reduced 63.06%	60,000 $4.84 Million
Q4 2018 Feb 05, 2019	BUY	$77.85 - $96.01 $2.52 Million - $3.11 Million	32,415 Added 24.93%	162,415 $15 Million
Q3 2018 Oct 03, 2018	BUY	$88.91 - $98.84 $5.33 Million - $5.93 Million	60,000 Added 85.71%	130,000 $12.3 Million
Q2 2018 Jul 20, 2018	SELL	$89.78 - $106.23 $12.3 Million - $14.5 Million	-136,700 Reduced 66.13%	70,000 $6.49 Million
Q1 2018 Apr 11, 2018	BUY	$92.01 - $123.21 $4.6 Million - $6.16 Million	50,000 Added 31.91%	206,700 $19.6 Million
Q4 2017 Jan 19, 2018	BUY	$89.56 - $98.21 $1.5 Million - $1.64 Million	16,700 Added 11.93%	156,700 $15.2 Million
Q3 2017 Oct 13, 2017	BUY	$69.85 - $89.22 $9.78 Million - $12.5 Million	140,000	140,000 $12.4 Million

Others Institutions Holding ABBV

# of Institutions

3,848

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $313B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account

Rhenman & Partners Asset Management Ab Abb Vie Inc. Transaction History